ArticleOncotarget2019

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Marilyne Labrie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.